Brief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
28/01/2026 16:06
Jan 28 (Reuters) - Biophytis SA ALBPS.PA: BIOPHYTIS SA: BIOPHYTIS ENTERS STRATEGIC AGREEMENT IN ASIA AND SECURES $20 MILLION FOR LAUNCH OF PHASE 3 TRIAL IN SARCOPENIA BIOPHYTIS SA: SIGNING OF A PROTOCOL AGREEMENT FOR THE CREATION OF A JOINT VENTURE IN HONG KONG Source text: [ID:n0001104659-26-007282] Further company coverage: ALBPS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon